• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性硬化症患者的长期生存经验。

Long-term survival experience of patients with multiple sclerosis.

作者信息

Pokorski R J

机构信息

Cologne Life Reinsurance Company, Stamford, CT 06905, USA.

出版信息

J Insur Med. 1997;29(2):101-6.

PMID:10169627
Abstract

BACKGROUND

Long-term survival of patients with multiple sclerosis is not well characterized because this disorder is relatively uncommon and subjects must be followed for decades after onset of symptoms. This paper reports comparative mortality experience of the world's largest series on an unselected cohort with multiple sclerosis.

RESULTS

Excess mortality varied with age, gender, duration since onset and diagnosis, calender year of onset, and clinical severity.

CONCLUSIONS

Compared to the general population in Denmark, patients with multiple sclerosis had less favorable survival experience during long-term follow-up.

摘要

背景

由于多发性硬化症相对不常见,且患者在症状出现后必须随访数十年,因此对该疾病患者的长期生存情况尚无充分描述。本文报告了世界上最大规模的未选择多发性硬化症队列的比较死亡率情况。

结果

超额死亡率随年龄、性别、起病和诊断后的病程、起病年份以及临床严重程度而变化。

结论

与丹麦普通人群相比,多发性硬化症患者在长期随访期间的生存情况较差。

相似文献

1
Long-term survival experience of patients with multiple sclerosis.多发性硬化症患者的长期生存经验。
J Insur Med. 1997;29(2):101-6.
2
[Survival in disseminated sclerosis in Denmark. A nation-wide study of the period 1948-1986].[丹麦播散性硬化症的生存率。1948 - 1986年全国性研究]
Ugeskr Laeger. 1995 Dec 18;157(51):7131-5.
3
Trends in survival and cause of death in Danish patients with multiple sclerosis.丹麦多发性硬化症患者的生存趋势及死因
Brain. 2004 Apr;127(Pt 4):844-50. doi: 10.1093/brain/awh104. Epub 2004 Feb 11.
4
Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway.多发性硬化症的生存率及死因:挪威西部50年随访结果
Mult Scler. 2008 Nov;14(9):1191-8. doi: 10.1177/1352458508093890. Epub 2008 Jul 16.
5
Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients.挪威多发性硬化症患者队列的超额死亡率和死因。
Mult Scler. 2009 Nov;15(11):1263-70. doi: 10.1177/1352458509107010. Epub 2009 Oct 7.
6
Prognostic factors for early severity in a childhood multiple sclerosis cohort.儿童多发性硬化症队列中早期严重程度的预后因素。
Pediatrics. 2006 Sep;118(3):1133-9. doi: 10.1542/peds.2006-0655.
7
Multiple sclerosis after infectious mononucleosis.传染性单核细胞增多症后发生的多发性硬化症。
Arch Neurol. 2007 Jan;64(1):72-5. doi: 10.1001/archneur.64.1.72.
8
Clinical characteristics and survival pattern of 1,153 patients with amyotrophic lateral sclerosis: experience over 30 years from India.1153例肌萎缩侧索硬化症患者的临床特征与生存模式:来自印度30多年的经验
J Neurol Sci. 2008 Sep 15;272(1-2):60-70. doi: 10.1016/j.jns.2008.04.034. Epub 2008 Jun 12.
9
Long-term prognosis of multiple sclerosis in Australia.
J Neurol Sci. 2007 May 15;256(1-2):35-8. doi: 10.1016/j.jns.2007.02.004. Epub 2007 Mar 21.
10
Comparison of the natural history and prognostic features of early onset and adult onset multiple sclerosis in Jordanian population.约旦人群中早发型和成年型多发性硬化症的自然病史及预后特征比较。
Clin Neurol Neurosurg. 2007 Jan;109(1):32-7. doi: 10.1016/j.clineuro.2006.06.002. Epub 2006 Jul 25.

引用本文的文献

1
Estimated health and economic effects associated with over- and under-exposure to solar ultraviolet radiation in Australia and New Zealand using the SUNEX simulation model.利用SUNEX模拟模型评估澳大利亚和新西兰因过度暴露和暴露不足于太阳紫外线辐射而产生的健康和经济影响。
Photochem Photobiol Sci. 2025 May 28. doi: 10.1007/s43630-025-00726-7.
2
Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model.奥法妥木单抗与特立氟胺治疗复发缓解型多发性硬化症的成本效益分析:一项10年马尔可夫模型研究
Clinicoecon Outcomes Res. 2025 Mar 20;17:217-232. doi: 10.2147/CEOR.S503842. eCollection 2025.
3
Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing-remitting multiple sclerosis: a simulation study.
natalizumab早期使用与延迟使用在高度活动性复发缓解型多发性硬化症中的成本-后果分析:一项模拟研究
J Neurol. 2025 Jan 17;272(2):153. doi: 10.1007/s00415-024-12723-4.
4
Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.从一个超过6000人的澳大利亚多发性硬化症(MS)患者大队列中估计残疾严重程度分类、MS表型和疾病修正治疗分类变化的转移概率。
Pharmacoeconomics. 2025 Feb;43(2):223-239. doi: 10.1007/s40273-024-01417-4. Epub 2024 Aug 2.
5
Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis.奥瑞珠单抗治疗伊朗复发型多发性硬化症患者的成本效益
Curr J Neurol. 2021 Jul 6;20(3):154-161. doi: 10.18502/cjn.v20i3.7691.
6
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.在加拿大,用奥法妥木单抗治疗复发缓解型多发性硬化症的成本-后果分析。
J Comp Eff Res. 2023 Sep;12(9):e220175. doi: 10.57264/cer-2022-0175. Epub 2023 Aug 22.
7
Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.奥瑞珠单抗治疗葡萄牙复发型和原发进展型多发性硬化症的成本效益分析。
Pharmacoecon Open. 2023 Mar;7(2):229-241. doi: 10.1007/s41669-022-00381-z. Epub 2022 Dec 1.
8
Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.奥法木单抗治疗加拿大复发缓解型多发性硬化症的成本效益分析。
Pharmacoecon Open. 2022 Nov;6(6):859-870. doi: 10.1007/s41669-022-00363-1. Epub 2022 Sep 15.
9
Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.在英国,对于疾病修饰疗法应答不足的复发缓解型多发性硬化症患者,那他珠单抗与芬戈莫德的疗效和成本效益比较。
Pharmacoeconomics. 2022 Mar;40(3):323-339. doi: 10.1007/s40273-021-01106-6. Epub 2021 Dec 18.
10
How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review.复发型多发性硬化症的经济学评估如何随时间演变?一项系统文献综述。
Neurol Ther. 2021 Dec;10(2):557-583. doi: 10.1007/s40120-021-00264-1. Epub 2021 Jul 19.